Shares of Skye Bioscience, Inc. (NASDAQ:SKYE - Get Free Report) traded up 23.1% during trading on Thursday . The company traded as high as $1.81 and last traded at $2.13. 320,782 shares changed hands during trading, a decline of 12% from the average session volume of 365,298 shares. The stock had previously closed at $1.73.
Analyst Ratings Changes
A number of equities analysts have commented on the stock. Craig Hallum reduced their price objective on shares of Skye Bioscience from $18.00 to $14.00 and set a "buy" rating for the company in a research report on Friday, March 21st. William Blair reaffirmed an "outperform" rating on shares of Skye Bioscience in a research report on Tuesday, May 20th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $16.60.
View Our Latest Stock Report on SKYE
Skye Bioscience Price Performance
The stock's 50-day moving average price is $2.17 and its 200-day moving average price is $1.92. The company has a market cap of $88.91 million, a P/E ratio of -3.50 and a beta of 1.69.
Skye Bioscience (NASDAQ:SKYE - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.31) by $0.03. As a group, analysts expect that Skye Bioscience, Inc. will post -1.04 EPS for the current fiscal year.
Institutional Investors Weigh In On Skye Bioscience
A number of institutional investors have recently modified their holdings of the business. Virtu Financial LLC acquired a new position in Skye Bioscience in the fourth quarter valued at about $29,000. Wells Fargo & Company MN raised its stake in Skye Bioscience by 49.0% in the fourth quarter. Wells Fargo & Company MN now owns 11,199 shares of the company's stock valued at $32,000 after purchasing an additional 3,684 shares in the last quarter. Two Sigma Advisers LP acquired a new position in Skye Bioscience in the fourth quarter valued at about $32,000. Capital Advisors Wealth Management LLC acquired a new position in Skye Bioscience in the first quarter valued at about $33,000. Finally, Nuveen LLC acquired a new position in Skye Bioscience in the first quarter valued at about $37,000. Institutional investors own 21.09% of the company's stock.
About Skye Bioscience
(
Get Free Report)
Skye Bioscience, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy.
Recommended Stories
Before you consider Skye Bioscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Skye Bioscience wasn't on the list.
While Skye Bioscience currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
